Insulin Regulation of Lipolysis and Lipolysis Proteins
Recruiting · NCT03866408 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.
Who can take part
Age range
18 Years to 55 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Men and Women between the ages of 18 and 55.
- Women will be premenopausal
- Non obese adults BMI between 18-25
- Obese BMI 30-38
Exclusion criteria
- , Pioglitazone package insert of contraindications for use:
- Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
- Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.
Where it is running
1 location listed across 1 US state.
- Mayo Clinic in Rochester - Rochester, Minnesota, United States